Abstract
In 2003, an estimated 20,000 new cases of breast cancer were diagnosed among black women in the United States, making it the most common malignancy in this population (1). The rates of breast cancer incidence in Caucasian women and African American women are 113.2 and 99.3 cases per 100,000, respectively (1). In West Africa, the founder population of most African Americans, breast cancer has been considered to be a rare virulent disease of young women. According to the International Agency of Research on Cancer, breast cancer incidence in seven African countries has doubled, going from an average of 15.3 cases per 100,000 in 1976 to 33.6 per 100,000 in 1998 (2) (also see the contribution of Max Parkin in this book). This could be due to an actual increase in incidence or may be the result of improved reporting of cases. Unfortunately, the large numbers of resource poor nations in Africa make it extremely difficult to have accurate estimates of the number of breast cancer cases diagnosed in those countries. Nevertheless, the incidence of cancer, in general, appears to have increased in Africa and may likely be related to the changes in social conditions, life-style, and emergence of the AIDS epidemic (3). Although the AIDS epidemic has resulted in a striking increase in the incidence of Kaposi’s sarcoma (now the most common cancer in Africa), there has not been an increase in incidence of AIDS-associated breast cancer (4, 5).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Anonymous: American Cancer Society (2003): Breast Cancer Facts and Figures., 2003.
Ijaduola TG, Smith EB: Pattern of breast cancer among white-American, African-American, and nonimmigrant west-African women. Journal of the National Medical Association. 1998;90:547–51.
Thomas JO: Acquired immunodeficiency syndrome-associated cancers in Sub-Saharan Africa. Semin Oncol 2001;28:198–206.
Bassett MT, Levy L, Chokunonga E, Mauchaza B, Ferlay J, Parkin DM: Cancer in the European population of Harare, Zimbabwe, 1990–1992. Int J Cancer 1995;63:24–8.
Sitas F, Pacella-Norman R, Carrara H, Patel M, Ruff P, Sur R, et al: The spectrum of HIV-1 related cancers in South Africa. Int J Cancer 2000;88:489–92.
Bah E, Parkin DM, Hall AJ, Jack AD, Whittle H: Cancer in the Gambia: 1988–97.Br J Cancer 2001;84:1207–14.
Solanke TF, Adebamowo CA: Reports of the workshop of the states of art in oncology in Ibadan and Ife. Ibadanl: National Headquarters of Cancer Registry in Nigeria, University College Hospital., 1996.
Echimane AK, Ahnoux AA, Adoubi I, Hien S, M’Bra K, D’Horpock A, et al: Cancer incidence in Abidjan, Ivory Coast: first results from the cancer registry, 1995–1997. Cancer 2000;89:653–63.
Bouchardy C, Parkin DM, Wanner P, Khlat M: Cancer mortality among north African migrants in France. Int J Epidemiol 1996;25:5–13.
Bedwani R, Abdel-Fattah M, El-Shazly M, Bassili A, Zaki A, Seif HA, et al: Profile of familial breast cancer in Alexandria, Egypt. Anticancer Res 2001;21:3011–4.
Anonymous: Breast Cancer Linkage Consortium. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 and BRCA2 mutations and sporadic cases. Lancet 1997;349:1505–10.
Hedenfalk I, Duggan D, Chen Y, Radmacher M, Bittner M, Simon R, et al: Gene-expression profiles in hereditary breast cancer. N Engl J Med 2001;344:539–48.
Anonymous: Breast Cancer Information Core Database: www.nhgri.nih.gov/ Intramural_research/Lab_transfer/Bic/resources. Breast Cancer Linkage Consortium. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 and BRCA2 mutations and sporadic cases. Lancet 1997;349:1505–10.
Olopade OI, Fackenthal JD, Dunston G, Tainsky MA, Collins F, Whitfield-Broome C: Breast cancer genetics in African Americans. Cancer 2003;97:236–45.
Mefford HC, Baumbach L, Panguluri RC, Whitfield-Broome C, Szabo C, Smith S, et al: Evidence for a BRCA1 founder mutation in families of West African ancestry. Am J Hum Genet 1999;65:575–8.
Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66–71.
Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, Tavtigian S, et al: BRCA1 mutations in primary breast and ovarian carcinomas. Science 1994;266:120–2.
Arena J, Smith S, Plewinska M, al. e: BRCA1 mutations in African American women. American Journal of Human Genetics 1996;59 (Suppl.).
Stoppa-Lyonnet D, Laurent-Puig P, Essioux L, Pages S, Ithier G, Ligot L, et al: BRCA1 sequence variations in 160 individuals referred to a breast/ovarian family cancer clinic. Institut Curie Breast Cancer Group (see comments). American Journal of Human Genetics 1997;60:1021–30.
Whitfield-Broome C, Duston GM, Brody LC: BRCA2 mutations in African Americans (abstract). Annual Meeting of the American Association for Cancer Research, 1999, p. 269.
Gao Q, Tomlinson G, Das S, Cummings S, Sveen L, Fackenthal J, et al: Prevalence of BRCA1 and BRCA2 mutations among clinic-based African American families with breast cancer. Hum Genet 2000;107:186–91.
Ganguly T, Citron M, Stott J, al. e: Novel BRCA mutations in African American individuals with breast and ovarian cancer. American Journal of Human Genetics 1998;63 (Suppl.):A69.
Kanaan Y, Kpenu E, Utley K, Brody L, Duston G, C W-B: BRCA2 mutations in African Americans. American Journal of Human Genetics 2000;67 (Suppl2):A455.
Dunning AM, Chiano M, Smith NR, Dearden J, Gore M, Oakes S, et al: Common BRCA1 variants and susceptibility to breast and ovarian cancer in the general population. Hum Mol Genet 1997;6:285–9.
Neuhausen S, Gilewski T, Norton L, Tran T, McGuire P, Swensen J, et al: Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nat Genet 1996;13:126–8.
Saifudeen Z, Dipp S, El-Dahr SS: A role for p53 in terminal epithelial cell differentiation. J Clin Invest 2002;109:1021–30.
May P, May E, May PR, Tuma AH, Dixon WJ, Yale C, et al: Twenty years of p53 research: structural and functional aspects of the p53 proteinSchizophrenia. A follow-up study of the results of five forms of treatment. Oncogene 1999;18:7621–36.
Nagai MA, Schaer Barbosa H, Zago MA, Araujo Silva W, Jr., Nishimoto IN, Salaorni S, et al: TP53 mutations in primary breast carcinomas from white and African-Brazilian patients. Int J Oncol 2003;23:189–96.
Blaszyk H, Vaughn CB, Hartmann A, McGovern RM, Schroeder JJ, Cunningham J, et al: Novel pattern of p53 gene mutations in an American black cohort with high mortality from breast cancer. Lancet 1994;343:1195–7.
Shiao YH, Chen VW, Lehmann HP, Wu XC, Correa P: Patterns of DNA ploidy and S-phase fraction associated with breast cancer survival in blacks and whites. Clin Cancer Res 1997;3:587–92.
Telatar M, Teraoka S, Wang Z, Chun HH, Liang T, Castellvi-Bel S, et al: Ataxia-telangiectasia: identification and detection of founder-effect mutations in the ATM gene in ethnic populations. Am J Hum Genet 1998;62:86–97.
Guillemette C, Millikan RC, Newman B, Housman DE: Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and association with breast cancer among African Americans. Cancer Res 2000;60:950–6.
Beutler E, Gelbart T, Demina A: Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci U S A 1998;95:8170–4.
Cummings S, Sellergren S, Olopade O, Matthews A, Schum P: Cancer risk perception and genetic counseling among African American women. Annual Meeting of the American Society of Clinical Oncology, 2000, p. 617A.
Schwartz MD, Hughes C, Roth J, Main D, Peshkin BN, Isaacs C, et al: Spiritual faith and genetic testing decisions among high-risk breast cancer probands. Cancer Epidemiol Biomarkers Prev 2000;9:381–5.
Begg CB: On the use of familial aggregation in population-based casse probands for calculating penetrance. J Natl Cancer Inst 2002;94:1221–26.
Struewing JP, Abeliovich D, Peretz T, Avishai N, Kaback MM, Collins FS, et al: The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet 1995;11:198–200.
Tonin P, Serova O, Lenoir G, al. e: BRCA1 mutations in Ashkenazi Jewish women (letter). American Journal of Human Genetics 1995;57:189.
Claes K, Machackova E, De Vos M, Poppe B, De Paepe A, Messiaen L: Mutation analysis of the BRCA1 and BRCA2 genes in the Belgian patient population and identification of a Belgian founder mutation BRCA1 IVS5 + 3A > G. Dis Markers 1999;15:69–73.
Petrij-Bosch A, Peelen T, van Vliet M, van Eijk R, Olmer R, Drusedau M, et al: BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet 1997;17:341–5.
Huusko P, Paakkonen K, Launonen V, Poyhonen M, Blanco G, Kauppila A, et al: Evidence of founder mutations in Finnish BRCA1 and BRCA2 families. Am J Hum Genet 1998;62:1544–8.
Johannsson O, Ostermeyer EA, Hakansson S, Friedman LS, Johansson U, Sellberg G, et al: Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden. Am J Hum Genet 1996;58:441–50.
Dorum A, Hovig E, Trope C, Inganas M, Moller P: Three per cent of Norwegian ovarian cancers are caused by BRCA1 1675delA or 1135insA. Eur J Cancer 1999;35:779–81.
Thorlacius S, Olafsdottir G, Tryggvadottir L, Neuhausen S, Jonasson JG, Tavtigian SV, et al: A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet 1996; 13:117–9.
Backe J, Hofferbert S, Skawran B, Dork T, Stuhrmann M, Karstens JH, et al: Frequency of BRCA1 mutation 5382insC in German breast cancer patients. Gynecol Oncol 1999;72:402–6.
Gayther SA, Harrington P, Russell P, Kharkevich G, Garkavtseva RF, Ponder BA: Frequently occurring germ-line mutations of the BRCA1 gene in ovarian cancer families from Russia. Am J Hum Genet 1997;60:1239–42
Csokay B, Tihomirova L, Stengrevics A, Sinicka O, Olah E: Strong founder effects in BRCA1 mutation carrier breast cancer patients from Latvia. Mutation in brief no. 258. Online. Hum Mutat 1999;14:92.
Tonin PM, Mes-Masson AM, Narod SA, Ghadirian P, Provencher D: Founder BRCA1 and BRCA2 mutations in French Canadian ovarian cancer cases unselected for family history. Clin Genet 1999;55:318–24.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer
About this chapter
Cite this chapter
Ikpatt, O.F., Olopade, O.I. (2006). Genetics of Breast Cancer in Women of African Descent: An Overview. In: Williams, C.K.O., Olopade, O.I., Falkson, C.I. (eds) Breast Cancer in Women of African Descent. Springer, Dordrecht. https://doi.org/10.1007/978-1-4020-3664-4_2
Download citation
DOI: https://doi.org/10.1007/978-1-4020-3664-4_2
Publisher Name: Springer, Dordrecht
Print ISBN: 978-1-4020-3682-8
Online ISBN: 978-1-4020-3664-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)